Zimbabwe has declined a major American health deal valued at $367m (£272m) over five years due to the United States' demand for confidential biological samples.
This rejection became public following a government memo dated December was disclosed, revealing that President Emmerson Mnangagwa felt the arrangement was "unbalanced".
A government representative later stated that the United States was requesting genetic material for scientific study and profit while was not willing to share the benefits from any future treatments.
"We will now turn to the challenging and unfortunate task of winding down our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had donated over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has urged further talks to find a deal acceptable to all parties so the nation's vital HIV programme can be sustained.
Wider Context
Zimbabwe's decision follows a similar case in neighbouring Kenya, where a court blocked a similar deal with the US after concerns were raised about the safety of citizens' health data.
After resuming office recently, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
USAID had administered aid for the American government, but Trump stated its expenditure was "inefficient" and his administration was seeking direct bilateral agreements to boost transparency and accountability.
As per reports, 16 African countries have to date agreed to similar agreements, constituting over $18.3bn in new funding.
Details of the Declined Deal
The money for Zimbabwe was intended to funded "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this partnership would have delivered immense advantages for the people of Zimbabwe, particularly the 1.2 million presently on antiretroviral therapy via American-funded initiatives," Tremont commented.
However, official spokesman Nick Mangwana maintained the proposed deal was "unequal".
"The proposal required Zimbabwe to provide its biological resources and data over an extended period, with no corresponding guarantee of benefiting from any scientific breakthroughs – like new medicines or tests – that might be developed from that shared data," Mangwana explained.
"Effectively, our nation would provide the raw materials for scientific discovery without any assurance that the resulting innovations would be available to our people should a new pandemic emerge."
National Interest and International Frameworks
Mangwana further pointed out that the US's withdrawal from the global health body and its push of bilateral health agreements were undermining structures previously set up through the global organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme created to deal with potential pandemics.
"This mechanism is designed to ensure that when a country contributes its samples, the benefits – such as medicines and cures – are distributed fairly, not commercialised exclusively by those with the funds to develop them."
The government's concerns over the US deal "are not meant as anti-American sentiment," he added.
"We are open to continued dialogue with our US partners on how subsequent co-operation might be designed in a way that honours the sovereignty and interests of each country."
Medical Community Reaction
A leading public health body said it understood the official position, but recommended that negotiations should continue since a large portion of the country's Aids initiatives relied on external financing.
"Where specific concerns arise, such as those relating to information security or implementation frameworks, these can often be addressed via technical clarification and mutually agreed protections," the group said.
This impasse emphasises the ongoing challenges between receiving much-needed international aid and protecting local interests in an ever more interconnected world.